Login to Your Account

FDA approves Regeneron’s Dupixent for atopic dermatitis

By Michael Fitzhugh
Staff Writer

Tuesday, March 28, 2017

Regeneron Pharmaceuticals Inc. won FDA approval for its biologic, Dupixent, as a treatment for adults with moderate to severe atopic dermatitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription